Company profile for Neowise Biotechnology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neowise Biotechnology is an innovative biotechnology company developing TCR-based cell therapies for solid tumors. Founded in 2020, it has built a high-throughput, ultra-sensitive platform integrating computational and experimental methods to identify natural TCRs targeting tumor antigens. This work supports CAST®, a globally leading experimentally validated tumor antigen–natural TCR pairing library, expanding therapeutic t...
Neowise Biotechnology is an innovative biotechnology company developing TCR-based cell therapies for solid tumors. Founded in 2020, it has built a high-throughput, ultra-sensitive platform integrating computational and experimental methods to identify natural TCRs targeting tumor antigens. This work supports CAST®, a globally leading experimentally validated tumor antigen–natural TCR pairing library, expanding therapeutic targets for solid tumors. Multiple programs have advanced into clinical trials with encouraging efficacy and safety.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
4th Floor, Building 2, 99 Jingu Rd, BioBay 3B, Suzhou Industrial Park
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

BPI Europe

BPI Europe

Not Confirmed

envelop Contact Supplier

BPI Europe

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty